Effect of Autograft CD34⁺ Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors

For children undergoing autologous hematopoietic stem cell transplantation for central nervous system tumors, increasing CD34+ cell dose was associated with significantly improved overall survival and progression-free survival, and lower relapse rates, without increased non-relapse mortality or endothelial-injury complications.